ProfileGDS5678 / 1427754_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 69% 69% 69% 68% 69% 70% 72% 69% 70% 69% 69% 67% 69% 69% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.2812769
GSM967853U87-EV human glioblastoma xenograft - Control 24.2468569
GSM967854U87-EV human glioblastoma xenograft - Control 34.2946469
GSM967855U87-EV human glioblastoma xenograft - Control 44.2592868
GSM967856U87-EV human glioblastoma xenograft - Control 54.2471269
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.3153370
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.5009872
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.276169
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.3267470
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.3200469
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.2694769
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0742567
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.2819969
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.2887869